{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T11:27:43Z","timestamp":1788175663040,"version":"build-2803163510"},"reference-count":194,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.ctrv.2024.102868","type":"journal-article","created":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T16:19:07Z","timestamp":1735316347000},"page":"102868","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["CAR-T cell therapy for breast cancer: Current status and future perspective"],"prefix":"10.1016","volume":"133","author":[{"given":"Giuseppe","family":"Buono","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Capozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Caputo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo Di","family":"Lauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Cianniello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Piezzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Cocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annarita","family":"Verrazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Tafuro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Calderaio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Calabrese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Nuzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8114-2577","authenticated-orcid":false,"given":"Martina","family":"Pagliuca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelino De","family":"Laurentiis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2024.102868_b0005","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023, CA","volume":"73","author":"Siegel","year":"2023","journal-title":"Cancer J Clin"},{"key":"10.1016\/j.ctrv.2024.102868_b0010","first-page":"105","article-title":"Triple negative breast cancer: Deciphering the biology and heterogeneity","volume":"18","author":"Uscanga-Perales","year":"2016","journal-title":"Med. Univ."},{"key":"10.1016\/j.ctrv.2024.102868_b0015","first-page":"1","article-title":"Triple-Negative Breast Cancer","volume":"2012","author":"Chu","year":"2012","journal-title":"Int. J. Breast Cancer"},{"key":"10.1016\/j.ctrv.2024.102868_b0020","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.tips.2015.08.009","article-title":"Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease","volume":"36","author":"Kalimutho","year":"2015","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.ctrv.2024.102868_b0025","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/PPO.0000000000000607","article-title":"Current State of Cell Therapies for Breast Cancer","volume":"28","author":"Gautam","year":"2022","journal-title":"Cancer J"},{"key":"10.1016\/j.ctrv.2024.102868_b0030","unstructured":"National Cancer Institute. Cold tumor., (n.d.). https:\/\/www.cancer. gov\/publications\/dictionaries\/cancer-terms\/def\/cold-tumor."},{"key":"10.1016\/j.ctrv.2024.102868_b0035","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.21037\/jtd.2020.03.119","article-title":"Innovative approaches to immunotherapy in breast cancer","volume":"12","author":"Quinn","year":"2020","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.ctrv.2024.102868_b0040","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.781848","article-title":"Identification of Breast Cancer Immune Subtypes by Analyzing Bulk Tumor and Single Cell Transcriptomes","volume":"9","author":"Yao","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.ctrv.2024.102868_b0045","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1126\/science.1235122","article-title":"Cancer Genome Landscapes","volume":"339","author":"Vogelstein","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.ctrv.2024.102868_b0050","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The Hallmarks of Cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.ctrv.2024.102868_b0055","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ctrv.2016.03.011","article-title":"The immune system and hormone-receptor positive breast cancer: Is it really a dead end?","volume":"46","author":"Dieci","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2024.102868_b0060","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.4049\/jimmunol.175.4.2666","article-title":"The Selective Estrogen Receptor Modulators, Tamoxifen and Raloxifene, Impair Dendritic Cell Differentiation and Activation","volume":"175","author":"Nalbandian","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.ctrv.2024.102868_b0065","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1158\/1078-0432.CCR-15-0204","article-title":"CCL2 and CCL5 Are Novel Therapeutic Targets for Estrogen-Dependent Breast Cancer","volume":"21","author":"Svensson","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2024.102868_b0070","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.path.2021.11.007","article-title":"A New Landscape of Testing and Therapeutics in Metastatic Breast Cancer","volume":"15","author":"Jagannathan","year":"2022","journal-title":"Surg Pathol Clin"},{"key":"10.1016\/j.ctrv.2024.102868_b0075","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41523-021-00362-1","article-title":"Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer","volume":"8","author":"Loi","year":"2022","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.ctrv.2024.102868_b0080","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.annonc.2021.05.355","article-title":"First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis","volume":"32","author":"Emens","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2024.102868_b0085","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","author":"Cortes","year":"2020","journal-title":"The Lancet 396"},{"key":"10.1016\/j.ctrv.2024.102868_b0090","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.breast.2016.07.015","article-title":"The genomic landscape of breast cancer and its interaction with host immunity","volume":"29","author":"Luen","year":"2016","journal-title":"Breast"},{"key":"10.1016\/j.ctrv.2024.102868_b0095","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1512942","article-title":"HER2 signaling regulates the tumor immune microenvironment and trastuzumab efficacy","volume":"8","author":"Triulzi","year":"2019","journal-title":"OncoImmunology"},{"key":"10.1016\/j.ctrv.2024.102868_b0100","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.610303","article-title":"The Crosstalk Between Tumor Cells and the Immune Microenvironment in Breast Cancer: Implications for Immunotherapy","volume":"11","author":"Salemme","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2024.102868_b0105","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41698-021-00163-6","article-title":"Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer","volume":"5","author":"Griguolo","year":"2021","journal-title":"npj Precis Oncol"},{"key":"10.1016\/j.ctrv.2024.102868_b0110","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jama.2018.19323","article-title":"Breast Cancer Treatment: A Review","volume":"321","author":"Waks","year":"2019","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.ctrv.2024.102868_b0115","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.clbc.2016.05.012","article-title":"Classification, Treatment Strategy, and Associated Drug Resistance in Breast Cancer","volume":"16","author":"Tang","year":"2016","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.ctrv.2024.102868_b0120","doi-asserted-by":"crossref","first-page":"675","DOI":"10.2147\/CMAR.S202965","article-title":"Strategies for Increasing the Effectiveness of Aromatase Inhibitors in Locally Advanced Breast Cancer: An Evidence-Based Review on Current Options","volume":"12","author":"Grizzi","year":"2020","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.ctrv.2024.102868_b0125","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.bbmt.2017.10.035","article-title":"Cellular Immunotherapy for Hematologic Malignancies: Beyond Bone Marrow Transplantation","volume":"24","author":"Cirillo","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.ctrv.2024.102868_b0130","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/PPO.0000000000000240","article-title":"Adoptive Cell Therapy for Metastatic Melanoma","volume":"23","author":"Merhavi-Shoham","year":"2017","journal-title":"Cancer J"},{"key":"10.1016\/j.ctrv.2024.102868_b0135","doi-asserted-by":"crossref","first-page":"589","DOI":"10.2217\/imt-2016-0086","article-title":"Cellular immunotherapy of cancer: an overview and future directions","volume":"9","author":"Tao","year":"2017","journal-title":"Immunotherapy"},{"key":"10.1016\/j.ctrv.2024.102868_b0140","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/d41573-019-00090-z","article-title":"The global pipeline of cell therapies for cancer","volume":"18","author":"Xin Yu","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ctrv.2024.102868_b0145","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00428-018-2484-0","article-title":"Adoptive cellular therapies: the current landscape","volume":"474","author":"Rohaan","year":"2019","journal-title":"Virchows Arch"},{"key":"10.1016\/j.ctrv.2024.102868_b0150","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1126\/science.aaa4967","article-title":"Adoptive cell transfer as personalized immunotherapy for human cancer","volume":"348","author":"Rosenberg","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.ctrv.2024.102868_b0155","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.3389\/fimmu.2018.02804","article-title":"Current State of Dendritic Cell-Based Immunotherapy: Opportunities for in vitro Antigen Loading of Different DC Subsets?","volume":"9","author":"Huber","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.ctrv.2024.102868_b0160","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1158\/1078-0432.CCR-15-1433","article-title":"Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy","volume":"22","author":"Maus","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2024.102868_b0165","doi-asserted-by":"crossref","first-page":"17576","DOI":"10.1073\/pnas.1420936111","article-title":"Molecular architecture of the \u03b1\u03b2 T cell receptor\u2013CD3 complex","volume":"111","author":"Birnbaum","year":"2014","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.ctrv.2024.102868_b0170","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/377032a0","article-title":"Molecular basis for interaction of the protein tyrosine kinase ZAP-70 with the T-cell receptor","volume":"377","author":"Hatada","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2024.102868_b0175","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1126\/science.281.5376.572","article-title":"Fidelity of T Cell Activation Through Multistep T Cell Receptor \u03b6 Phosphorylation","volume":"281","author":"Kersh","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.ctrv.2024.102868_b0180","doi-asserted-by":"crossref","first-page":"472","DOI":"10.3390\/cells8050472","article-title":"Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy","volume":"8","author":"Stoiber","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.ctrv.2024.102868_b0185","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/imr.12131","article-title":"Design and development of therapies using chimeric antigen receptor-expressing T cells","volume":"257","author":"Dotti","year":"2014","journal-title":"Immunol Rev"},{"key":"10.1016\/j.ctrv.2024.102868_b0190","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/0006-291X(87)90502-X","article-title":"Expression of chimeric receptor composed of immunoglobulin-derived V resions and T-cell receptor-derived C regions","volume":"149","author":"Kuwana","year":"1987","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.ctrv.2024.102868_b0195","doi-asserted-by":"crossref","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-06-1183","article-title":"A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer","volume":"12","author":"Kershaw","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2024.102868_b0200","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1038\/mt.2009.83","article-title":"Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo","volume":"17","author":"Milone","year":"2009","journal-title":"Mol Ther"},{"key":"10.1016\/j.ctrv.2024.102868_b0205","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/sj.leu.2403302","article-title":"Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia","volume":"18","author":"Imai","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.ctrv.2024.102868_b0210","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.ymthe.2005.04.016","article-title":"A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells","volume":"12","author":"Pul\u00e8","year":"2005","journal-title":"Mol Ther"},{"key":"10.1016\/j.ctrv.2024.102868_b0215","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1073\/pnas.0813101106","article-title":"Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains","volume":"106","author":"Carpenito","year":"2009","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.ctrv.2024.102868_b0220","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ccell.2015.09.004","article-title":"Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells","volume":"28","author":"Zhao","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ctrv.2024.102868_b0225","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41551-018-0235-9","article-title":"Programming CAR-T cells to kill cancer","volume":"2","author":"Labanieh","year":"2018","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.ctrv.2024.102868_b0230","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.96976","article-title":"Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation","volume":"3","author":"Guedan","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.ctrv.2024.102868_b0235","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/mt.2009.210","article-title":"Chimeric Antigen Receptors Combining 4-1BB and CD28 Signaling Domains Augment PI3kinase\/AKT\/Bcl-XL Activation and CD8+ T Cell\u2013mediated Tumor Eradication","volume":"18","author":"Zhong","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/j.ctrv.2024.102868_b0240","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s00262-020-02735-0","article-title":"Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives","volume":"70","author":"Qu","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ctrv.2024.102868_b0245","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3390\/biom10020263","article-title":"Recent Advances in Allogeneic CAR-T Cells","volume":"10","author":"Kim","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.ctrv.2024.102868_b0250","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41416-018-0325-1","article-title":"Teaching an old dog new tricks: next-generation CAR T cells","volume":"120","author":"Tokarew","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2024.102868_b0255","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.3389\/fimmu.2018.02486","article-title":"Expanding the Therapeutic Window for CAR T Cell Therapy in Solid Tumors: The Knowns and Unknowns of CAR T Cell Biology","volume":"9","author":"Watanabe","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.ctrv.2024.102868_b0260","doi-asserted-by":"crossref","first-page":"e1049","DOI":"10.1002\/cti2.1049","article-title":"Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations","volume":"8","author":"Weinkove","year":"2019","journal-title":"Clin Transl Immunol"},{"key":"10.1016\/j.ctrv.2024.102868_b0265","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","article-title":"Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells","volume":"44","author":"Kawalekar","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.ctrv.2024.102868_b0270","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood-2013-10-535245","article-title":"ICOS-based chimeric antigen receptors program bipolar TH17\/TH1 cells","volume":"124","author":"Guedan","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2024.102868_b0275","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1158\/0008-5472.CAN-15-0159","article-title":"Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice","volume":"75","author":"Liu","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2024.102868_b0280","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","article-title":"Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours","volume":"20","author":"Flugel","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102868_b0285","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1080\/17460441.2021.1929920","article-title":"Approaches for refining and furthering the development of CAR-based T cell therapies for solid malignancies","volume":"16","author":"Hull","year":"2021","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.ctrv.2024.102868_b0290","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s00005-021-00640-7","article-title":"Prospects for Development of Induced Pluripotent Stem Cell-Derived CAR-Targeted Immunotherapies","volume":"70","author":"Mazza","year":"2022","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"10.1016\/j.ctrv.2024.102868_b0295","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3389\/fimmu.2019.00189","article-title":"Individualization of Hematopoietic Stem Cell Transplantation Using Alpha\/Beta T-Cell Depletion","volume":"10","author":"R\u00e5destad","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.ctrv.2024.102868_b0300","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/nri2200","article-title":"Specificity of T-cell alloreactivity","volume":"7","author":"Felix","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ctrv.2024.102868_b0305","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1158\/0008-5472.CAN-14-3321","article-title":"Multiplex Genome-Edited T-cell Manufacturing Platform for \u201cOff-the-Shelf\u201d Adoptive T-cell Immunotherapies","volume":"75","author":"Poirot","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2024.102868_b0310","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1182\/blood-2012-01-405365","article-title":"A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR","volume":"119","author":"Torikai","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2024.102868_b0315","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaj2013","article-title":"Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells","volume":"9","author":"Qasim","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ctrv.2024.102868_b0320","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2024.102868_b0325","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"\u2018Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ctrv.2024.102868_b0330","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.copbio.2018.01.025","article-title":"A guide to manufacturing CAR T cell therapies","volume":"53","author":"Vormittag","year":"2018","journal-title":"Curr Opin Biotechnol"},{"key":"10.1016\/j.ctrv.2024.102868_b0335","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1080\/14712598.2021.1857361","article-title":"Lymphodepletion strategies to potentiate adoptive T-cell immunotherapy \u2013 what are we doing; where are we going?","volume":"21","author":"Bechman","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.ctrv.2024.102868_b0340","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.18632\/oncotarget.27731","article-title":"Targeted lymphodepletion with a CD45-directed antibody radioconjugate as a novel conditioning regimen prior to adoptive cell therapy","volume":"11","author":"Dawicki","year":"2020","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2024.102868_b0345","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","article-title":"Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias","volume":"118","author":"Brentjens","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2024.102868_b0350","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric Antigen Receptor\u2013Modified T Cells for Acute Lymphoid Leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2024.102868_b0355","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/s41591-020-01225-1","article-title":"TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers","volume":"27","author":"Nagarsheth","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2024.102868_b0360","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","article-title":"Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy","volume":"375","author":"Brown","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2024.102868_b0510","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.cellimm.2018.05.004","article-title":"A novel AXL chimeric antigen receptor endows T cells with anti-tumor effects against triple negative breast cancers","volume":"331","author":"Wei","year":"2018","journal-title":"Cell Immunol"},{"key":"10.1016\/j.ctrv.2024.102868_b0515","first-page":"1","article-title":"Engineered IL-7 Receptor Enhances the Therapeutic Effect of AXL-CAR-T Cells on Triple-Negative Breast Cancer","volume":"2020","author":"Zhao","year":"2020","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.ctrv.2024.102868_b0480","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.126345","article-title":"ROR1-CAR T cells are effective against lung and breast cancer in advanced microphysiologic 3D tumor models","volume":"4","author":"Wallstabe","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.ctrv.2024.102868_b0430","doi-asserted-by":"crossref","first-page":"11054","DOI":"10.18632\/aging.102510","article-title":"EGFR-specific CAR-T cells trigger cell lysis in EGFR-positive TNBC","volume":"11","author":"Liu","year":"2019","journal-title":"Aging"},{"key":"10.1016\/j.ctrv.2024.102868_b0435","doi-asserted-by":"crossref","first-page":"e1135","DOI":"10.1002\/cti2.1135","article-title":"EGFR\u2010targeted CAR\u2010T cells are potent and specific in suppressing triple\u2010negative breast cancer both in vitro and in vivo","volume":"9","author":"Xia","year":"2020","journal-title":"Clin Transl Immunol"},{"key":"10.1016\/j.ctrv.2024.102868_b0365","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00262-017-2089-5","article-title":"Targeting and suppression of HER3-positive breast cancer by T lymphocytes expressing a heregulin chimeric antigen receptor","volume":"67","author":"Zuo","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ctrv.2024.102868_b0395","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.3389\/fonc.2020.01143","article-title":"The Third Generation Anti-HER2 Chimeric Antigen Receptor Mouse T Cells Alone or Together With Anti-PD1 Antibody Inhibits the Growth of Mouse Breast Tumor Cells Expressing HER2 in vitro and in Immune Competent Mice","volume":"10","author":"Li","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2024.102868_b0400","first-page":"688","article-title":"Overcome trastuzumab resistance of breast cancer using anti-HER2 chimeric antigen receptor T cells and PD1 blockade","volume":"10","author":"Li","year":"2020","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.ctrv.2024.102868_b0970","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2020.04.008","article-title":"Trastuzumab derived HER2-specific CARs for the treatment of trastuzumab-resistant breast cancer: CAR T cells penetrate and eradicate tumors that are not accessible to antibodies","volume":"484","author":"Sz\u00f6\u0151r","year":"2020","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ctrv.2024.102868_b0975","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.3390\/ijms21031039","article-title":"A Small Number of HER2 Redirected CAR T Cells Significantly Improves Immune Response of Adoptively Transferred Mouse Lymphocytes against Human Breast Cancer Xenografts","volume":"21","author":"T\u00f3th","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ctrv.2024.102868_b0530","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2020.104041","article-title":"Oncolytic adenovirus targeting TGF-\u03b2 enhances anti-tumor responses of mesothelin-targeted chimeric antigen receptor T cell therapy against breast cancer","volume":"348","author":"Li","year":"2020","journal-title":"Cell Immunol"},{"key":"10.1016\/j.ctrv.2024.102868_b0550","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.3389\/fimmu.2019.01149","article-title":"CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth","volume":"10","author":"Zhou","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.ctrv.2024.102868_b0620","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13045-016-0285-y","article-title":"Effective adoptive immunotherapy of triple-negative breast cancer by folate receptor-alpha redirected CAR T cells is influenced by surface antigen expression level","author":"Song","year":"2016","journal-title":"J. Hematol. Oncol.J Hematol Oncol 9"},{"key":"10.1016\/j.ctrv.2024.102868_b0640","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1158\/0008-5472.CAN-16-1911","article-title":"TEM8\/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer","volume":"78","author":"Byrd","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2024.102868_b0660","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1158\/1078-0432.CCR-13-2218","article-title":"T Lymphocytes Redirected against the Chondroitin Sulfate Proteoglycan-4 Control the Growth of Multiple Solid Tumors both In Vitro and In Vivo","volume":"20","author":"Geldres","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2024.102868_b0675","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.573823","article-title":"Intercellular Adhesion Molecule-1 as Target for CAR-T-Cell Therapy of Triple-Negative Breast Cancer","volume":"11","author":"Wei","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.ctrv.2024.102868_b0705","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13045-018-0635-z","article-title":"Control of triple-negative breast cancer using ex vivo self-enriched, costimulated NKG2D CAR T cells, J. Hematol. Oncol","volume":"11","author":"Han","year":"2018","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.ctrv.2024.102868_b0745","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1683345","article-title":"GD2-targeted chimeric antigen receptor T cells prevent metastasis formation by elimination of breast cancer stem-like cells","volume":"9","author":"Seitz","year":"2020","journal-title":"OncoImmunology"},{"key":"10.1016\/j.ctrv.2024.102868_b0370","doi-asserted-by":"crossref","first-page":"11561","DOI":"10.1007\/s00432-023-04996-5","article-title":"T cells expressing a HER2-specific chimeric antigen receptor as treatment for breast cancer","volume":"149","author":"Xie","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102868_b0375","unstructured":"BPX-601 and BPX-603 Trials Discontinued in Advanced Solid Tumors, (2023). https:\/\/www.onclive.com\/view\/bpx-601-and-bpx-603-trials-discontinued-in-advanced-solid-tumors."},{"key":"10.1016\/j.ctrv.2024.102868_b0380","unstructured":"Bellicum Discontinues Phase 1\/2 Trials and Initiates Evaluation of Strategic Alternatives, (2023). https:\/\/ir.bellicum.com\/news-releases\/news-release-details\/bellicum-discontinues-phase-12-trials-and-initiates-evaluation."},{"key":"10.1016\/j.ctrv.2024.102868_b0385","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/s41417-021-00359-9","article-title":"Ghorbani Alvanegh, Combination therapy with CAR T cells and oncolytic viruses: a new era in cancer immunotherapy","volume":"29","author":"Rezaei","year":"2022","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.ctrv.2024.102868_b0390","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1089\/hum.2020.278","article-title":"Combining Oncolytic Viruses with Chimeric Antigen Receptor T Cell Therapy","volume":"32","author":"McGrath","year":"2021","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.ctrv.2024.102868_b0420","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1038\/mt.2015.71","article-title":"Clinical Scale Zinc Finger Nuclease-mediated Gene Editing of PD-1 in Tumor Infiltrating Lymphocytes for the Treatment of Metastatic Melanoma","volume":"23","author":"Beane","year":"2015","journal-title":"Mol Ther"},{"key":"10.1016\/j.ctrv.2024.102868_b0425","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1186\/1471-2164-8-258","article-title":"EGFR associated expression profiles vary with breast tumor subtype","volume":"8","author":"Hoadley","year":"2007","journal-title":"BMC Genomics"},{"key":"10.1016\/j.ctrv.2024.102868_b0440","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.1111\/febs.12393","article-title":"The epidermal growth factor receptor variant III (EGFR v III): where wild things are altered","volume":"280","author":"Gan","year":"2013","journal-title":"FEBS J"},{"key":"10.1016\/j.ctrv.2024.102868_b0445","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1023\/B:BREA.0000041585.26734.f9","article-title":"EGFR and EGFRvIII Expression in Primary Breast Cancer and Cell Lines","volume":"87","author":"Rae","year":"2004","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2024.102868_b0450","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1158\/0008-5472.CAN-11-2656","article-title":"Epidermal Growth Factor Receptor Variant III Contributes to Cancer Stem Cell Phenotypes in Invasive Breast Carcinoma","volume":"72","author":"Del Vecchio","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2024.102868_b0455","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa0984","article-title":"A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma","volume":"9","author":"O\u2019Rourke","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ctrv.2024.102868_b0460","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1172\/JCI87366","article-title":"Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies","volume":"126","author":"Ruella","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ctrv.2024.102868_b0465","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1093\/neuonc\/nox182","article-title":"Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma","volume":"20","author":"Bielamowicz","year":"2018","journal-title":"Neuro-Oncol."},{"key":"10.1016\/j.ctrv.2024.102868_b0470","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1177\/2472555216689659","article-title":"Antiproliferative and Apoptotic Effects of Novel Anti-ROR1 Single-Chain Antibodies in Hematological Malignancies","volume":"22","author":"Aghebati-Maleki","year":"2017","journal-title":"SLAS Discov."},{"key":"10.1016\/j.ctrv.2024.102868_b0475","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00428-016-1911-3","article-title":"Expression of ROR1 has prognostic significance in triple negative breast cancer","volume":"468","author":"Chien","year":"2016","journal-title":"Virchows Arch"},{"key":"10.1016\/j.ctrv.2024.102868_b0485","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS18-P2-09-13","article-title":"Abstract P2-09-13: A phase I study of adoptive immunotherapy for ROR1+ advanced triple negative breast cancer (TNBC) with defined subsets of autologous T cells expressing a ROR1-specific chimeric antigen receptor (ROR1-CAR)","volume":"79","author":"Specht","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2024.102868_b0490","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/bjc.2013.31","article-title":"High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer","volume":"108","author":"Zagouri","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2024.102868_b0495","first-page":"1152","article-title":"Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer, Cancer","volume":"5","author":"Tchou","year":"2017","journal-title":"Immunol Res"},{"key":"10.1016\/j.ctrv.2024.102868_b0500","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1158\/2767-9764.CRC-22-0486","article-title":"Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma","volume":"3","author":"Shah","year":"2023","journal-title":"Cancer Res Commun"},{"key":"10.1016\/j.ctrv.2024.102868_b0505","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s12943-019-1090-3","article-title":"AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications","volume":"18","author":"Zhu","year":"2019","journal-title":"Mol Cancer"},{"key":"10.1016\/j.ctrv.2024.102868_b0525","article-title":"Mesothelin Expression in Triple Negative Breast Carcinomas Correlates Significantly with Basal-Like Phenotype","volume":"9","author":"Tozbikian","year":"2014","journal-title":"Distant Metastases and Decreased Survival, PLoS ONE"},{"key":"10.1016\/j.ctrv.2024.102868_b0535","first-page":"1791","article-title":"Inhibiting TGF\u03b2 Signaling in CAR T-Cells May Significantly Enhance Efficacy of Tumor Immunotherapy","volume":"130","author":"Vong","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2024.102868_b0540","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/j.humpath.2013.04.010","article-title":"MUC1 is expressed at high frequency in early-stage basal-like triple-negative breast cancer","volume":"44","author":"Siroy","year":"2013","journal-title":"Hum Pathol"},{"key":"10.1016\/j.ctrv.2024.102868_b0545","article-title":"MUC1 facilitates metabolomic reprogramming in triple-negative breast cancer","volume":"12","author":"Goode","year":"2017","journal-title":"PLoSONE"},{"key":"10.1016\/j.ctrv.2024.102868_b0555","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.immuni.2016.05.014","article-title":"Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma","volume":"44","author":"Posey","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.ctrv.2024.102868_b0560","doi-asserted-by":"crossref","unstructured":"A. Kozlowska, Y. Zhang, J. Fritz, S. Wang, R. Codde, E. Argus, S. Ibitokou, V. Richardson, S. Jain, M. Richter, D. Patil, Y. Tan, M. Tong, L. Yao, M. Ghoddusi, E. Ostertag, J. Coronella, D. Shedlock, 120 P-MUC1C-ALLO1: An allogeneic car-t for multiple solid tumor indications, in: Regul. Young Investig. Award Abstr., BMJ Publishing Group Ltd, 2020: p. A73.1-A73. DOI: 10.1136\/jitc-2020-SITC2020.0120.","DOI":"10.1136\/jitc-2020-SITC2020.0120"},{"key":"10.1016\/j.ctrv.2024.102868_b0565","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.omtn.2022.06.003","article-title":"Cas-CLOVER is a novel high-fidelity nuclease for safe and robust generation of TSCM-enriched allogeneic CAR-T cells","volume":"29","author":"Madison","year":"2022","journal-title":"Mol. Ther. - Nucleic Acids"},{"issue":"2018","key":"10.1016\/j.ctrv.2024.102868_b0570","first-page":"1907","article-title":"Claudin 6 is a carcinoembryonic antigen with cancer stem cell marker features","volume":"78","author":"T\u00fcreci","year":"1907","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2024.102868_b0575","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1126\/science.aay5967","article-title":"An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors","volume":"367","author":"Reinhard","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ctrv.2024.102868_b0580","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.878209","article-title":"CAR-T Cell Performance: How to Improve Their Persistence?","volume":"13","author":"L\u00f3pez-Cantillo","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.ctrv.2024.102868_b0585","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/nature18300","article-title":"Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy","volume":"534","author":"Kranz","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2024.102868_b0590","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41586-020-2537-9","article-title":"An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma","volume":"585","author":"Sahin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2024.102868_b0595","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1038\/s41591-023-02612-0","article-title":"CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial","volume":"29","author":"Mackensen","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2024.102868_b0600","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.canlet.2020.07.044","article-title":"CAR T-cell therapy for triple-negative breast cancer: Where we are","volume":"491","author":"Xie","year":"2020","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ctrv.2024.102868_b0605","article-title":"Folate Receptor-\u03b1 (FOLR1) Expression and Function in Triple Negative Tumors","volume":"10","author":"Necela","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ctrv.2024.102868_b0610","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/2193-1801-1-22","article-title":"Folate receptor alpha (FRA) expression in breast cancer: identification of a new molecular subtype and association with triple negative disease","volume":"1","author":"O\u2019Shannessy","year":"2012","journal-title":"Springerplus"},{"key":"10.1016\/j.ctrv.2024.102868_b0615","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.clbc.2017.03.007","article-title":"Folate Receptor Alpha Expression Is Associated With Increased Risk of Recurrence in Triple-negative Breast Cancer","volume":"17","author":"Ginter","year":"2017","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.ctrv.2024.102868_b0625","first-page":"1311","article-title":"Elevated levels of tumour endothelial marker-8 in human breast cancer and its clinical significance","volume":"29","author":"Davies","year":"2006","journal-title":"Int J Oncol"},{"key":"10.1016\/j.ctrv.2024.102868_b0630","doi-asserted-by":"crossref","first-page":"5821","DOI":"10.1158\/0008-5472.CAN-13-1080","article-title":"ANTXR1, a Stem Cell-Enriched Functional Biomarker, Connects Collagen Signaling to Cancer Stem-like Cells and Metastasis in Breast Cancer","volume":"73","author":"Chen","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2024.102868_b0635","first-page":"3417","article-title":"Tumor endothelial marker 8 expression in triple-negative breast cancer","volume":"31","author":"Gutwein","year":"2011","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ctrv.2024.102868_b0645","doi-asserted-by":"crossref","first-page":"R58","DOI":"10.1186\/bcr2895","article-title":"Chondroitin sulfates play a major role in breast cancer metastasis: a role for CSPG4 and CHST11gene expression in forming surface P-selectin ligands in aggressive breast cancer cells","volume":"13","author":"Cooney","year":"2011","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ctrv.2024.102868_b0650","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1093\/jnci\/djq343","article-title":"CSPG4 Protein as a New Target for the Antibody-Based Immunotherapy of Triple-Negative Breast Cancer","volume":"102","author":"Wang","year":"2010","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"10.1016\/j.ctrv.2024.102868_b0655","doi-asserted-by":"crossref","first-page":"530","DOI":"10.7150\/thno.10824","article-title":"Theranostic Impact of NG2\/CSPG4 Proteoglycan in Cancer","volume":"5","author":"Nicolosi","year":"2015","journal-title":"Theranostics"},{"key":"10.1016\/j.ctrv.2024.102868_b0665","first-page":"218","article-title":"Evidence for Cell Adhesion-Mediated Drug Resistance of Multiple Myeloma Cells in Vivo","volume":"21","author":"Schmidmaier","year":"2006","journal-title":"Int J Biol Markers"},{"key":"10.1016\/j.ctrv.2024.102868_b0670","doi-asserted-by":"crossref","first-page":"14710","DOI":"10.1073\/pnas.1408556111","article-title":"ICAM-1 as a molecular target for triple negative breast cancer","volume":"111","author":"Guo","year":"2014","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.ctrv.2024.102868_b0680","doi-asserted-by":"crossref","first-page":"28989","DOI":"10.18632\/oncotarget.25615","article-title":"The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target","volume":"9","author":"Goldenberg","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2024.102868_b0685","first-page":"1846","article-title":"The killing effect of novel bi-specific Trop2\/PD-L1 CAR-T cell targeted gastric cancer","volume":"9","author":"Zhao","year":"2019","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.ctrv.2024.102868_b0690","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1002\/ijc.28775","article-title":"NKG2D signaling in cancer immunosurveillance","volume":"136","author":"L\u00f3pez-Soto","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2024.102868_b0695","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1089\/hum.2012.143","article-title":"Chimeric NKG2D CAR-Expressing T Cell-Mediated Attack of Human Ovarian Cancer Is Enhanced by Histone Deacetylase Inhibition","volume":"24","author":"Song","year":"2013","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.ctrv.2024.102868_b0700","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.4049\/jimmunol.1200796","article-title":"Comprehensive Analysis of NKG2D Ligand Expression and Release in Leukemia: Implications for NKG2D-Mediated NK Cell Responses","volume":"189","author":"Hilpert","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.ctrv.2024.102868_b0710","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3393\/ac.2019.11.13","article-title":"A Review of the Role of Carcinoembryonic Antigen in Clinical Practice","volume":"35","author":"Hall","year":"2019","journal-title":"Ann. Coloproctology"},{"key":"10.1016\/j.ctrv.2024.102868_b0715","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0133830","article-title":"Elevated Levels of Serum Tumor Markers CEA and CA15-3 Are Prognostic Parameters for Different Molecular Subtypes of Breast Cancer","volume":"10","author":"Shao","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ctrv.2024.102868_b0720","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.ymthe.2017.03.010","article-title":"Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA+ Metastatic Colorectal Cancers","volume":"25","author":"Zhang","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.ctrv.2024.102868_b0725","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1371345","article-title":"GD2-targeting therapy: a comparative analysis of approaches and promising directions","volume":"15","author":"Philippova","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.ctrv.2024.102868_b0730","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.3389\/fonc.2020.01000","article-title":"Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy","volume":"10","author":"Nazha","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2024.102868_b0735","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1172\/JCI59735","article-title":"Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis","volume":"122","author":"Battula","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ctrv.2024.102868_b0740","doi-asserted-by":"crossref","first-page":"31592","DOI":"10.18632\/oncotarget.16363","article-title":"GD2 expression in breast cancer","volume":"8","author":"Orsi","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2024.102868_b0750","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ctrv.2024.102868_b0755","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1365-2567.2009.03072.x","article-title":"Switch from perforin\u2010expressing to perforin\u2010deficient CD8 + T cells accounts for two distinct types of effector cytotoxic T lymphocytes in vivo","volume":"128","author":"Meiraz","year":"2009","journal-title":"Immunology"},{"key":"10.1016\/j.ctrv.2024.102868_b0760","first-page":"1274","article-title":"CD30-Redirected Chimeric Antigen Receptor T Cells Target CD30+ and CD30\u2212 Embryonal Carcinoma via Antigen-Dependent and Fas\/FasL Interactions, Cancer","volume":"6","author":"Hong","year":"2018","journal-title":"Immunol Res"},{"key":"10.1016\/j.ctrv.2024.102868_b0765","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.3390\/ijms20061283","article-title":"Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells","volume":"20","author":"Benmebarek","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ctrv.2024.102868_b0770","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1182\/blood.2019002121","article-title":"Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity","volume":"135","author":"Dufva","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2024.102868_b0775","first-page":"36","article-title":"High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model, Cancer","volume":"6","author":"Richman","year":"2018","journal-title":"Immunol Res"},{"key":"10.1016\/j.ctrv.2024.102868_b0780","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1007\/s00262-017-2034-7","article-title":"The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity","volume":"66","author":"Thistlethwaite","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ctrv.2024.102868_b0785","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1200\/JCO.2006.05.9964","article-title":"Treatment of Metastatic Renal Cell Carcinoma With Autologous T-Lymphocytes Genetically Retargeted Against Carbonic Anhydrase IX: First Clinical Experience","volume":"24","author":"Lamers","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102868_b0790","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/j.ctrv.2024.102868_b0795","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.1158\/1078-0432.CCR-15-0428","article-title":"Bioactivity and Safety of IL13R\u03b12-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma","volume":"21","author":"Brown","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2024.102868_b0800","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40164-022-00363-1","article-title":"Breast cancer heterogeneity and its implication in personalized precision therapy","volume":"12","author":"Guo","year":"2023","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.ctrv.2024.102868_b0405","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/s41571-022-00689-z","article-title":"Clinical implications of T cell exhaustion for cancer immunotherapy","volume":"19","author":"Chow","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102868_b0410","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1158\/1078-0432.CCR-16-1300","article-title":"Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition","volume":"23","author":"Ren","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2024.102868_b0415","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1158\/0008-5472.CAN-15-3352","article-title":"TALEN-Mediated Inactivation of PD-1 in Tumor-Reactive Lymphocytes Promotes Intratumoral T-cell Persistence and Rejection of Established Tumors","volume":"76","author":"Menger","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2024.102868_b0805","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jtct.2022.04.008","article-title":"Socioeconomic and Racial Disparity in Chimeric Antigen Receptor T Cell Therapy Access","volume":"28","author":"Ahmed","year":"2022","journal-title":"Transplant. Cell. Ther."},{"key":"10.1016\/j.ctrv.2024.102868_b0810","doi-asserted-by":"crossref","first-page":"e786","DOI":"10.1016\/S2352-3026(22)00226-5","article-title":"Access to and affordability of CAR T-cell therapy in multiple myeloma: an EBMT position paper","volume":"9","author":"Gagelmann","year":"2022","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.ctrv.2024.102868_b0815","doi-asserted-by":"crossref","first-page":"7200","DOI":"10.1038\/s41467-021-27312-6","article-title":"Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients","volume":"12","author":"Maschan","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.ctrv.2024.102868_b0820","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41409-022-01866-5","article-title":"Decentralized manufacturing of anti CD19 CAR-T cells using CliniMACS Prodigy\u00ae: real-world experience and cost analysis in India","volume":"58","author":"Palani","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ctrv.2024.102868_b0825","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1038\/s41591-024-03231-z","article-title":"CAR-T and cellular gene therapies are too expensive","volume":"30","author":"Dropuli\u0107","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2024.102868_b0830","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s10875-012-9689-9","article-title":"Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using Chimeric Antigen Receptors Engineered to Provide Complementary Signaling","volume":"32","author":"Wilkie","year":"2012","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.ctrv.2024.102868_b0835","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nbt.2459","article-title":"Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells","volume":"31","author":"Kloss","year":"2013","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.ctrv.2024.102868_b0840","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1158\/2159-8290.CD-17-1298","article-title":"Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment","volume":"8","author":"Sukumaran","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2024.102868_b0845","article-title":"Abstract PO074: Logic-gating HER2 CAR-T to the tumor microenvironment mitigates on-target, off-tumor toxicity without compromising cytotoxicity against HER2-over-expressing tumors, Cancer Immunol","volume":"9","author":"Zhang","year":"2021","journal-title":"Philos Phenomenol Res"},{"key":"10.1016\/j.ctrv.2024.102868_b0850","doi-asserted-by":"crossref","first-page":"39833","DOI":"10.1038\/srep39833","article-title":"An oxygen sensitive self-decision making engineered CAR T-cell","volume":"7","author":"Juillerat","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.ctrv.2024.102868_b0855","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.3389\/fonc.2019.01448","article-title":"Target-Dependent Expression of IL12 by synNotch Receptor-Engineered NK92 Cells Increases the Antitumor Activities of CAR-T Cells","volume":"9","author":"Luo","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2024.102868_b0860","doi-asserted-by":"crossref","DOI":"10.1126\/science.aba1624","article-title":"Synthetic cytokine circuits that drive T cells into immune-excluded tumors","author":"Allen","year":"2022","journal-title":"Science 378"},{"key":"10.1016\/j.ctrv.2024.102868_b0865","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41571-021-00476-2","article-title":"Immunogenicity of CAR T cells in cancer therapy","volume":"18","author":"Wagner","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102868_b0870","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.cell.2022.03.023","article-title":"Modular design of synthetic receptors for programmed gene regulation in cell therapies","volume":"185","author":"Zhu","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.ctrv.2024.102868_b0875","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006597","article-title":"PD-1\u2013 and CTLA-4\u2013Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses","volume":"5","author":"Fedorov","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ctrv.2024.102868_b0880","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102868_b0885","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/s41589-021-00932-1","article-title":"Engineering CAR-T cells to activate small-molecule drugs in situ","volume":"18","author":"Gardner","year":"2022","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.ctrv.2024.102868_b0890","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1126\/science.abq6990","article-title":"The future of engineered immune cell therapies","volume":"378","author":"Irvine","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.ctrv.2024.102868_b0895","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ctrv.2024.102868_b0900","unstructured":"Autologous HER2-targeted Dual-switch CAR-T Cells BPX-603 (Code C176990), (n.d.). https:\/\/ncit.nci.nih.gov\/ncitbrowser\/pages\/concept_details.jsf?dictionary=NCI_Thesaurus&version=23.10e&code=C176990&ns=ncit&type=properties&key=null&b=1&n=0&vse=null."},{"key":"10.1016\/j.ctrv.2024.102868_b0905","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12896-019-0537-3","article-title":"Modulation of chimeric antigen receptor surface expression by a small molecule switch","volume":"19","author":"Juillerat","year":"2019","journal-title":"BMC Biotech"},{"key":"10.1016\/j.ctrv.2024.102868_b0910","first-page":"999","article-title":"CRASH-IT Switch Enables Reversible and Dose-Dependent Control of TCR and CAR T-cell Function, Cancer","volume":"9","author":"Sahillioglu","year":"2021","journal-title":"Immunol Res"},{"key":"10.1016\/j.ctrv.2024.102868_b0915","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.ccell.2022.08.008","article-title":"High-performance multiplex drug-gated CAR circuits","volume":"40","author":"Li","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ctrv.2024.102868_b0920","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1126\/science.ade0156","article-title":"Multidimensional control of therapeutic human cell function with synthetic gene circuits","volume":"378","author":"Li","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.ctrv.2024.102868_b0925","doi-asserted-by":"crossref","first-page":"674","DOI":"10.3390\/cancers11050674","article-title":"CAR T-Cells Targeting the Integrin \u03b1v\u03b26 and Co-Expressing the Chemokine Receptor CXCR2 Demonstrate Enhanced Homing and Efficacy against Several Solid Malignancies","volume":"11","author":"Whilding","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.ctrv.2024.102868_b0930","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nm.3833","article-title":"Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes","volume":"21","author":"Caruana","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2024.102868_b0935","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13045-019-0763-0","article-title":"Engineering switchable and programmable universal CARs for CAR T therapy, J. Hematol. Oncol","volume":"12","author":"Liu","year":"2019","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.ctrv.2024.102868_b0940","doi-asserted-by":"crossref","first-page":"31368","DOI":"10.18632\/oncotarget.15572","article-title":"Retargeting of T lymphocytes to PSCA- or PSMA positive prostate cancer cells using the novel modular chimeric antigen receptor platform technology \u201cUniCAR,","volume":"8","author":"Feldmann","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2024.102868_b0945","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3389\/fonc.2019.00176","article-title":"The Emergence of Universal Immune Receptor T Cell Therapy for Cancer","volume":"9","author":"Minutolo","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2024.102868_b0950","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/CJI.0000000000000032","article-title":"Universal Artificial Antigen Presenting Cells to Selectively Propagate T Cells Expressing Chimeric Antigen Receptor Independent of Specificity","volume":"37","author":"Rushworth","year":"2014","journal-title":"J Immunother"},{"key":"10.1016\/j.ctrv.2024.102868_b0955","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.cell.2018.05.030","article-title":"Increasing T Cell Versatility with SUPRA CARs","volume":"173","author":"Chen","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.ctrv.2024.102868_b0960","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.cell.2018.03.038","article-title":"Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses","volume":"173","author":"Cho","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.ctrv.2024.102868_b0965","volume":"3","author":"Maher","year":"2022","journal-title":"Med."}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030573722400197X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030573722400197X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T03:30:39Z","timestamp":1738812639000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030573722400197X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":194,"alternative-id":["S030573722400197X"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2024.102868","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CAR-T cell therapy for breast cancer: Current status and future perspective","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2024.102868","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102868"}}